Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

A Phase 2 Study of Dynamic BH3 Profiling (DBP) Guided Combination Therapy in Subjects With R/R AML (PRIME)

14 november 2026 bijgewerkt door: Jacqueline Garcia, MD, Dana-Farber Cancer Institute

A Phase 2 Study Using the Dynamic BH3 Profiling Assay to Guide Venetoclax-Based Combination Therapy for Participants With Relapsed or Refractory Acute Myeloid Leukemia

This study aims to evaluate the feasibility and efficacy of using the dynamic BH3 profiling (DBP) assay as a biomarker to guide venetoclax-based combination therapy for participants with relapsed or refractory acute myeloid leukemia (AML).

Studie Overzicht

Gedetailleerde beschrijving

This is a phase 2, single-center, interventional study evaluating the feasibility and efficacy of using the dynamic BH3 profiling (DBP) assay as a biomarker to guide venetoclax-based combination therapy for participants with relapsed or refractory acute myeloid leukemia (AML). The DBP assay is a flow cytometry-based test (functional biomarker) performed on subject biospecimen (bone marrow aspirate) to measure drug-induced apoptotic priming against a pre-set panel of drugs, which can help to identify potentially effective drug combinations. Eligible participants will undergo biomarker screening, and the Protocol Tumor Board will review DBP results and clinical data to assign treatment. Following subjects on assigned treatment for safety and efficacy is part of the trial. Up to six venetoclax-based combination regimens are available. Participants will continue to receive assigned therapy as long as they are benefiting and tolerating treatment. The study will enroll up to 40 participants for treatment assignments, with up to 75 screened. Study procedures include screening, biomarker testing, treatment, disease response assessments, and follow-up for up to one year after last treatment.

Studietype

Ingrijpend

Inschrijving (Geschat)

40

Fase

  • Fase 2

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Willing to undergo a bone marrow aspirate for biomarker testing.

  • Participants must have a diagnosis by WHO 2006 of one of the following:

    • Participants with Relapsed AML must have at least 5% morphologic marrow blasts to be eligible. Extramedullary disease allowed but marrow involvement required.
    • Participants with Refractory AML are defined as those without a complete remission after two courses (or cycles) of any remission-induction regimen (intensive chemotherapy or less intensive regimen such as hypomethylating agent-venetoclax based treatment or low-dose cytarabine agent-venetoclax based treatment).
    • Participants with Secondary AML arising out of a previously treated prior myeloid neoplasm treated with intensive chemotherapy or at least two cycles of HMA/venetoclax-based treatment.
    • Participants may also be Relapsed/Refractory.
  • ECOG performance status ≤ 2 (see Appendix A)

  • Participants decline, must not be eligible or are not recommended by treating provider to receive immediate allogeneic transplantation or available FDA-approved AML regimens.

  • Participants must meet the following organ function as defined below:

    • total bilirubin ≤ 3 x institutional upper limit of normal (ULN) unless considered to be due to leukemic organ involvement or Gilbert's disease. For participants with Gilbert's syndrome, participants may enroll if direct bilirubin ≤ 3xULN
    • AST(SGOT) and ALT(SGPT) ≤ 3 × institutional ULN
    • Creatinine clearance ≥ 30mL/min using Cockroft Gault formula
  • If male, even if surgically sterilized (i.e., status post-vasectomy), participant must agree to use adequate barrier contraception prior to the study, for the duration of study participation, and 6 months after completion of study drug administration, or agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, postovulation methods for the female partner] withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception.)

  • If female, participant must be either:

    • Postmenopausal (surgically sterile or age > 55 years with no menses for 12 or more months without an alternative medical cause or age 55 or less with no menses for 12 or more months without an alternative medical cause AND an FSH level >40 IU/L) or
    • Women of childbearing potential must agree to use adequate contraception (defined as 1 highly effective method [hormonal] and 1 additional effective [barrier] method of birth control at the same time) 30 days prior to study entry, for the duration of study participation, and through 6 months after the last dose of study drug or agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the participant. Female and male condoms should not be used together. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post ovulation methods), withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception.
    • Women of childbearing potential: Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
    • Women of childbearing potential: Participant must have a negative serum beta-HCG test result (local labs are allowed) at screening. Repeat testing is required within 72 hours prior to first study dose (local labs are allowed).
  • White blood cell count < 25,000/L prior to first dose on study protocol treatment. Hydroxyurea or leukapheresis are permitted to meet this criterion (hydroxyurea may be resumed after biomarker collection takes place).

  • Ability to understand and the willingness to sign a written informed consent document.

  • For combination venetoclax, azacitidine, and tagraxofusp assignment, must also meet the following organ function criteria:

    • Creatinine clearance (measured by Cockcroft-Gault formula or measured by 24-hour urine collection) ≥ 45 mL/minute; participants between 18 and 74 years of age may have creatinine clearance ≥ 30 mL/minute
    • Albumin > 3.2 g/dL (administration of albumin is permitted to achieve albumin eligibility if the baseline serum albumin is ≥ 3.0g/dL)
    • Total bilirubin ≤ 1.5 x upper limit of normal (ULN) except in participants with Gilbert's syndrome. Participants with Gilbert's syndrome may enroll if direct bilirubin ≤ 3 x ULN of the direct bilirubin.
  • For combination venetoclax, azacitidine, and revumenib assignment, must also meet the following organ function criteria:

  • Total bilirubin ≤ 2.0 x upper limit of normal (ULN) except in participants with Gilbert's syndrome. Participants with Gilbert's syndrome may enroll if direct bilirubin ≤ 3.0 x ULN of the direct bilirubin.

Exclusion Criteria:

  • During biomarker collection: For purpose of dynamic BH3 profiling assay (biomarker) to optimize cell viability, participants must not be on any anti-leukemic therapy for at least 5 days prior to bone marrow aspirate collection with the exception of hydroxyurea which must be held at least 48 hours prior to aspirate collection. Note: hydroxyurea use is allowed immediately after bone marrow aspirate collection if clinically indicated.

  • Participants who have had chemotherapy (with exception of hydroxyurea and/or dexamethasone which are allowed) or radiotherapy or investigational therapy within 5 half-lives or 14 days (whichever is shorter) prior to starting treatment on study.

  • More than two prior AML-directed salvage regimens defined as any line of therapy given for a relapsed or refractory indication (excluding initial induction regimen, allogeneic transplant, donor lymphocyte infusion, hydroxyurea, cytarabine for cytoreduction purposes).

  • Venetoclax within 14 days prior to starting treatment on study.

  • Any prior investigational therapy-related AEs must be grade 1 or at baseline prior to first dose on study (except for alopecia).

  • Has known acute promyelocytic leukemia.

  • Concurrent use of medications that are moderate or strong CYP450 inducers within 7 days of first dose on study. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the participant will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine or herbal product. Please consult FDA website as appropriate: https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers

  • Consumption of grapefruit or grapefruit products, Seville oranges, or star fruit within 3 days prior to first dose on study.

  • Participants diagnosed with another malignancy that have either received treatment within 2 years prior to first dose on study or are currently recommended to receive treatment (indicating this other malignancy is active). Exceptions include 1) participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone resection, 2) previous malignancy confined and surgically resected (or treated with other modalities) with curative intent are allowed, 3) any breast, reproductive or prostate cancer that is well controlled with hormonal or topical therapies.

  • Major surgery within 14 days before first dose of any study drug.

  • Participants with known, active and uncontrolled heart failure (NYHA Class III or IV), clinically significant arrhythmia, symptomatic cardiomyopathy, unstable angina or myocardial ischemia infarction within last 6 months, and clinically significant pulmonary hypertension requiring pharmacologic therapy. Clinically significant arrhythmia is defined as having one of the following: history of polymorphic ventricular fibrillation or torsade de pointes, permanent atrial fibrillation (continuous for ≥ 6 months), persistent atrial fibrillation (sustained and lasting > 7 days and/or requiring cardioversion in the 4 weeks before screening), and grade 3 atrial fibrillation (symptomatic and incompletely controlled medically in the past 6 months). Participants with paroxysmal atrial fibrillation or < Gr 3 atrial fibrillation for period of at least 6 months are permitted to enroll provided that their rate is controlled on a stable regimen if medically indicated.

  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to any assigned study agents.

  • Known allergy to both xanthine oxidase inhibitors and rasburicase.

  • Known HIV seropositive. HIV testing is not required.

  • Participants with known, active chronic hepatitis B virus (HBV) infection. Exception: Participants with undetectable HBV load by polymerase chain reaction (PCR), without liver-related complications, and on definitive HBV therapy are eligible for study. Serologic evidence of prior vaccination is sufficient to participate in the trial (vaccination however is not required for trial).

  • Participants with known chronic hepatitis C virus (HCV) infection requiring treatment. However, if a participant with a history of HCV infection has received definitive therapy (and is now HCV viral load negative), or if a participant has a reactive HCV antibody test but has an undetectable viral load by PCR, then he/she would be eligible.

  • Immediate life-threatening, severe complications of leukemia such as uncontrolled bleeding, respiratory failure, or coagulopathy.

  • Symptomatic or (known) active CNS involvement of AML. Prophylactic intra-thecal chemotherapy is permitted.

  • Participants with active or uncontrolled infection at time of first dose of treatment on study. Prophylaxis is allowed. Participants receiving anti-microbial agents including antibiotics, antiviral or antifungal therapies are allowed if hemodynamically stable and afebrile for 72 hours (unless fever is thought to be from underlying leukemia).

  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that in the opinion of the investigator may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and/or would make the participant inappropriate for enrollment into this study.

  • Vaccination with live, attenuated vaccines within 4 weeks prior to initiation of study treatment or anticipation of need for such a vaccine during the study. (COVID19 vaccinations are allowed.)

  • Malabsorption syndrome or other clinically significant condition (including difficulty swallowing oral medications) that would preclude enteral administration.

  • Female participants who are lactating and breastfeeding, intention to participate in IVF (in vitro fertilization), or intending to donate eggs (ova) during course of this trial or 6 months after receiving last dose of study drug.

  • Male participants who intend to donate sperm during the course of this study or 6 months after receiving their last dose of study drug(s).

  • Participants assigned to combination venetoclax and gilteritinib are excluded with the following: Heart rate corrected QT interval (QTcF) ≥ 500 msec or with other factors that increase the risk of QT prolongation or arrhythmic events (e.g., heart failure, hypokalemia, family history of long QT interval syndrome).

  • Participants assigned to combination venetoclax, azacitidine, and tagraxofusp are excluded with any clinically significant cardiac disease or abnormalities defined as:

    • LVEF is less than lower limit of normal by MUGA scan or echocardiogram.
    • Myocardial infarction, unstable angina, or evidence of poorly controlled atrial fibrillation leading to a complication or severely symptomatic such that daily activity is affected within 12 months prior to first dose on study.
    • Any history of congenital long QT syndrome sustained ventricular tachycardia requiring intervention, ventricular fibrillation, or torsades de pointes.
    • Presence at screening of second- or third-degree AV block without a permanent pacemaker, bi-fascicular block (right bundle branch block [RBBB] with left anterior hemiblock), or complete left bundle branch block.
    • QTc using Fridericia's correction (QTcF) >480 msec. Triplicate ECG requested for tagraxofusp at screening.
  • Participants assigned to combination venetoclax, azacitidine, and revumenib are excluded with the following:

    • Participants <40 kg in weight.
    • Concurrent use of moderate or strong CYP3A4 inducers (prohibited)
    • LVEF is <50% by MUGA scan or echocardiogram,
    • QTc using Fridericia's correction (QTcF) >450 msec,
    • History of acute pancreatitis within 6 months of first dose on study or history of chronic pancreatitis,
    • Known cirrhosis with a Child-Pugh score of B or C.
    • Known personal or family history of long QT syndrome.
    • Required use of QT-prolonging agents (except for those with low risk for QT prolongation and used as standard supportive medications e.g. famotidine, Bactrim, azoles, anti-emetics, antibacterial agents such as levofloxacin, ciprofloxacin or azithromycin, diphenhydramine).
    • Any of the following within 6 months before first dose on study: myocardial infarction, uncontrolled/unstable angina, congestive heart failure (NYHA Class ≥II), life-threatening uncontrolled arrhythmia, cerebrovascular accident, or transient ischemic attack. Participants with controlled atrial fibrillation are allowed to enroll.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Niet-gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Venetoclax + Low-Dose Cytarabine

Participants receive venetoclax in combination with low-dose cytarabine (Ven/AraC). Assignment is based on evidence of drug-induced apoptotic priming from the DBP assay and confirmation that the participant meets regimen-specific eligibility requirements.

Dynamic BH3 Profiling is performed on myeloblasts obtained from a bone marrow aspirate to assess drug-induced apoptotic priming, using cytochrome c retention as the assay readout. The report evaluates venetoclax-based combinations and includes comparisons that are intra-patient and inter-patient (against a pooled historical dataset). The Protocol Tumor Board reviews the DBP report, screening findings, drug-specific eligibility, and patient and disease history to determine treatment assignment. The protocol defines feasibility as successful assay performance and delivery of the DBP report within five days of sample receipt.

Venetoclax is a selective BCL-2 inhibitor administered as a component of every protocol treatment regimen. Target dose and duration are specific to each treatment regimen. Doses may be reduced when given with azoles or other interacting agents, and treatment may be held for clinically significant tumor lysis syndrome.

Cytarabine will be tested in combination with venetoclax at different dosing strategies. Low-dose cytarabine will be combined with venetoclax in Arm 1. It is also administered as part of the venetoclax-cladribine-based regimen in Arm 6, at low or mid-intensity dosing based on age and fitness, and will be age-adjusted for safety.

Experimenteel: Venetoclax + Gilteritinib

Participantsreceive venetoclax in combination with gilteritinib (Ven/Gilt). Assignment is based on evidence of drug-induced apoptotic priming from the DBP assay and confirmation that the participant meets regimen-specific eligibility requirements.

Dynamic BH3 Profiling is performed on myeloblasts obtained from a bone marrow aspirate to assess drug-induced apoptotic priming, using cytochrome c retention as the assay readout. The report evaluates venetoclax-based combinations and includes comparisons that are intra-patient and inter-patient (against a pooled historical dataset). The Protocol Tumor Board reviews the DBP report, screening findings, drug-specific eligibility, and patient and disease history to determine treatment assignment. The protocol defines feasibility as successful assay performance and delivery of the DBP report within five days of sample receipt.

Venetoclax is a selective BCL-2 inhibitor administered as a component of every protocol treatment regimen. Target dose and duration are specific to each treatment regimen. Doses may be reduced when given with azoles or other interacting agents, and treatment may be held for clinically significant tumor lysis syndrome.

Gilteritinib is administered in combination with venetoclax to participants assigned to Treatment 2 based on DBP findings and confirmation of regimen-specific eligibility.

Experimenteel: Venetoclax + Azacitidine + Tagraxofusp

Participants receive venetoclax, azacitidine, and tagraxofusp (Ven/Aza/Tag). Assignment is based on evidence of drug-induced apoptotic priming from the DBP assay and confirmation that the participant meets regimen-specific eligibility requirements.

Dynamic BH3 Profiling is performed on myeloblasts obtained from a bone marrow aspirate to assess drug-induced apoptotic priming, using cytochrome c retention as the assay readout. The report evaluates venetoclax-based combinations and includes comparisons that are intra-patient and inter-patient (against a pooled historical dataset). The Protocol Tumor Board reviews the DBP report, screening findings, drug-specific eligibility, and patient and disease history to determine treatment assignment. The protocol defines feasibility as successful assay performance and delivery of the DBP report within five days of sample receipt.

Venetoclax is a selective BCL-2 inhibitor administered as a component of every protocol treatment regimen. Target dose and duration are specific to each treatment regimen. Doses may be reduced when given with azoles or other interacting agents, and treatment may be held for clinically significant tumor lysis syndrome.

Azacitidine is administered with venetoclax and tagraxofusp in Arm 3 and with venetoclax and revumenib in Arm 5. Dosing of azacitidine is standard at 75 mg/m² daily on Days 1-7.

Tagraxofusp is administered in combination with venetoclax and azacitidine to participants assigned to Treatment 3 based on DBP findings and confirmation of regimen-specific eligibility.

Experimenteel: Venetoclax + Decitabine

Participants receive venetoclax in combination with decitabine (Ven/Dec). Assignment is based on evidence of drug-induced apoptotic priming from the DBP assay and confirmation that the participant meets regimen-specific eligibility requirements.

Dynamic BH3 Profiling is performed on myeloblasts obtained from a bone marrow aspirate to assess drug-induced apoptotic priming, using cytochrome c retention as the assay readout. The report evaluates venetoclax-based combinations and includes comparisons that are intra-patient and inter-patient (against a pooled historical dataset). The Protocol Tumor Board reviews the DBP report, screening findings, drug-specific eligibility, and patient and disease history to determine treatment assignment. The protocol defines feasibility as successful assay performance and delivery of the DBP report within five days of sample receipt.

Venetoclax is a selective BCL-2 inhibitor administered as a component of every protocol treatment regimen. Target dose and duration are specific to each treatment regimen. Doses may be reduced when given with azoles or other interacting agents, and treatment may be held for clinically significant tumor lysis syndrome.

Decitabine is administered in combination with venetoclax to participants assigned to Treatment 4 based on DBP findings and confirmation of regimen-specific eligibility.

Experimenteel: Venetoclax + Azacitidine + Revumenib

Participants receive venetoclax, azacitidine, and revumenib (Ven/Aza/Rev). Assignment is based on evidence of drug-induced apoptotic priming from the DBP assay and confirmation that the participant meets regimen-specific eligibility requirements.

Dynamic BH3 Profiling is performed on myeloblasts obtained from a bone marrow aspirate to assess drug-induced apoptotic priming, using cytochrome c retention as the assay readout. The report evaluates venetoclax-based combinations and includes comparisons that are intra-patient and inter-patient (against a pooled historical dataset). The Protocol Tumor Board reviews the DBP report, screening findings, drug-specific eligibility, and patient and disease history to determine treatment assignment. The protocol defines feasibility as successful assay performance and delivery of the DBP report within five days of sample receipt.

Venetoclax is a selective BCL-2 inhibitor administered as a component of every protocol treatment regimen. Target dose and duration are specific to each treatment regimen. Doses may be reduced when given with azoles or other interacting agents, and treatment may be held for clinically significant tumor lysis syndrome.

Azacitidine is administered with venetoclax and tagraxofusp in Arm 3 and with venetoclax and revumenib in Arm 5. Dosing of azacitidine is standard at 75 mg/m² daily on Days 1-7.

Revumenib is administered orally and in combination with venetoclax and azacitidine to participants assigned to Treatment 3 based on DBP findings and confirmation of regimen-specific eligibility.

Experimenteel: Venetoclax + Cladribine-Based Regimen

Participants receive a 28-day-cycle venetoclax and cladribine-based regimen. The low-intensity strategy is intended for participants older than 70 years or medically unfit and consists of venetoclax, cladribine, and low-dose cytarabine. The mid-intensity strategy is intended for fit participants 70 years or younger and consists of venetoclax, cladribine, and mid-dose cytarabine.

For the low-intensity strategy, venetoclax is administered on Days 1-21. Cladribine 5 mg/m² is administered daily on Days 1-5, and cytarabine 20 mg is administered twice daily on Days 1-10. Induction may continue for up to two cycles according to response. Venetoclax dose and duration may be modified for tolerability and drug interactions.

For the mid-intensity strategy, venetoclax is administered on Days 2-8. Cladribine 5 mg/m² is administered daily on Days 1-5, and cytarabine is administered once daily on Days 1-5 (age-adjusted). Induction may continue for up to two cycles according to response.

Dynamic BH3 Profiling is performed on myeloblasts obtained from a bone marrow aspirate to assess drug-induced apoptotic priming, using cytochrome c retention as the assay readout. The report evaluates venetoclax-based combinations and includes comparisons that are intra-patient and inter-patient (against a pooled historical dataset). The Protocol Tumor Board reviews the DBP report, screening findings, drug-specific eligibility, and patient and disease history to determine treatment assignment. The protocol defines feasibility as successful assay performance and delivery of the DBP report within five days of sample receipt.

Venetoclax is a selective BCL-2 inhibitor administered as a component of every protocol treatment regimen. Target dose and duration are specific to each treatment regimen. Doses may be reduced when given with azoles or other interacting agents, and treatment may be held for clinically significant tumor lysis syndrome.

Cladribine is administered with venetoclax and low- or mid-intensity cytarabine in a combination regimen. ladribine is administered at 5 mg/m² daily on Days 1-5 of a 28-day cycle.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Feasibility Rate of Dynamic BH3 Profiling (DBP)
Tijdsspanne: Within 5 days of receipt of a viable sample.

Feasibility rate is defined as the proportion of participants whose bone marrow specimens are collected and received by the laboratory for DBP testing, for whom the samples are successfully processed and a DBP report is generated.

Within 5 days of receipt of a viable sample.
Overall Response Rate (ORR)
Tijdsspanne: Assessed at the end of Cycles 1, 2, and 4 (each cycle is 28 days), and every 3 cycles thereafter for up to 1 year, with an end-of-treatment assessment (up to 2 years; up to 3 months or 2 cycles for the cladribine/venetoclax arm).

ORR is defined as the proportion of participants with relapsed/refractory acute myeloid leukemia (R/R AML) assigned to protocol therapy by the Protocol Tumor Board who achieve complete remission (CR), complete remission with partial hematologic recovery (CRh), or complete remission with incomplete count recovery (CRi), according to the European LeukemiaNet (ELN) response criteria for AML. CR requires bone marrow blasts <5%, absence of circulating blasts and extramedullary disease, absolute neutrophil count (ANC) ≥1,000/μL, and platelet count ≥100,000/μL. CRh requires all other CR criteria to be met, with ANC ≥500/μL and platelet count ≥50,000/μL. CRi requires all other CR criteria to be met, but with ANC <1,000/μL and/or platelet count <100,000/μL.

Assessed at the end of Cycles 1, 2, and 4 (each cycle is 28 days), and every 3 cycles thereafter for up to 1 year, with an end-of-treatment assessment (up to 2 years; up to 3 months or 2 cycles for the cladribine/venetoclax arm).
Reasons for Unsuccessful Assignment to DBP-Guided Therapy
Tijdsspanne: During the screening period (up to 21 days).

Reasons for unsuccessful assignment to protocol therapy despite available drug nominations from DBP, or participant withdrawal, will be summarized by category using frequencies and percentages.

During the screening period (up to 21 days).

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Grade 3 or Higher Hematologic Adverse Events Rate
Tijdsspanne: Assessed at each scheduled treatment visit (each cycle is 28 days) and 30 days after the last dose of study treatment (up to 2 years plus 30 days; up to 3 months or 2 cycles plus 30 days for the cladribine/venetoclax arm).

Grade 3 or higher hematologic adverse events rate is defined as the proportion of participants who experience at least one Grade 3 or higher hematologic adverse event, as graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 6.0.

Assessed at each scheduled treatment visit (each cycle is 28 days) and 30 days after the last dose of study treatment (up to 2 years plus 30 days; up to 3 months or 2 cycles plus 30 days for the cladribine/venetoclax arm).
Grade 3 or Higher Non-Hematologic Adverse Events Rate
Tijdsspanne: Assessed at each scheduled treatment visit (each cycle is 28 days) and 30 days after the last dose of study treatment (anticipated up to 2 years plus 30 days; up to 3 months or 2 cycles plus 30 days for the cladribine/venetoclax arm).

Grade 3 or higher non-hematologic adverse events rate is defined as the proportion of participants who experience at least one Grade 3 or higher non-hematologic adverse event, as graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 6.0.

Assessed at each scheduled treatment visit (each cycle is 28 days) and 30 days after the last dose of study treatment (anticipated up to 2 years plus 30 days; up to 3 months or 2 cycles plus 30 days for the cladribine/venetoclax arm).
Overall Response Rate (ORR) by Assigned Treatment Regimen
Tijdsspanne: Assessed at each scheduled treatment visit (each cycle is 28 days) and 30 days after the last dose of study treatment (up to 2 years plus 30 days; up to 3 months or 2 cycles plus 30 days for the cladribine/venetoclax arm).

Grade 3 or higher non-hematologic adverse events rate is defined as the proportion of participants who experience at least one Grade 3 or higher non-hematologic adverse event, as graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 6.0.

Assessed at each scheduled treatment visit (each cycle is 28 days) and 30 days after the last dose of study treatment (up to 2 years plus 30 days; up to 3 months or 2 cycles plus 30 days for the cladribine/venetoclax arm).
Overall Response Rate (ORR) by Each Treatment Regimen
Tijdsspanne: Assessed at the end of Cycles 1, 2, and 4 (each cycle is 28 days), and every 3 cycles thereafter for up to 1 year, with an end-of-treatment assessment (up to 2 years; up to 3 months or 2 cycles for the cladribine/venetoclax arm).

ORR is defined as the proportion of participants with relapsed/refractory acute myeloid leukemia (R/R AML) assigned to protocol therapy by the Protocol Tumor Board who achieve complete remission (CR), complete remission with partial hematologic recovery (CRh), or complete remission with incomplete count recovery (CRi), according to the ELN response criteria for AML. CR requires bone marrow blasts <5%, absence of circulating blasts and extramedullary disease, absolute neutrophil count (ANC) ≥1,000/μL, and platelet count ≥100,000/μL. CRh requires all other CR criteria to be met, with ANC ≥500/μL and platelet count ≥50,000/μL. CRi requires all other CR criteria to be met, but with ANC <1,000/μL and/or platelet count <100,000/μL.

Assessed at the end of Cycles 1, 2, and 4 (each cycle is 28 days), and every 3 cycles thereafter for up to 1 year, with an end-of-treatment assessment (up to 2 years; up to 3 months or 2 cycles for the cladribine/venetoclax arm).
Duration of Response (DOR)
Tijdsspanne: Assessed at each scheduled treatment visit (each cycle is 28 days) and 30 days after the last dose of study treatment (up to 2 years plus 30 days; up to 3 months or 2 cycles plus 30 days for the cladribine/venetoclax arm).

DOR is measured from the time response criteria are first met for CR, CRi, CRh, or complete remission with incomplete platelet recovery (CRp), whichever occurs first, until the first date of objectively documented recurrent or progressive disease. According to the ELN response criteria for AML, CR requires bone marrow blasts <5%, absence of circulating blasts and extramedullary disease, ANC ≥1,000/μL, and platelet count ≥100,000/μL. CRi meets all other CR criteria but has ANC <1,000/μL and/or platelet count <100,000/μL. CRh meets all other CR criteria with ANC ≥500/μL and platelet count ≥50,000/μL. CRp meets all other CR criteria but has platelet count <100,000/μL with ANC ≥1,000/μL. Recurrent disease is defined as the reappearance of disease following CR, CRh, or CRi, characterized by bone marrow blasts ≥5%, reappearance of blasts in at least two peripheral blood samples collected at least one week apart, or development of extramedullary disease. Disease progression is defined accord

Assessed at each scheduled treatment visit (each cycle is 28 days) and 30 days after the last dose of study treatment (up to 2 years plus 30 days; up to 3 months or 2 cycles plus 30 days for the cladribine/venetoclax arm).
6-Month Progression-Free Survival (PFS6)
Tijdsspanne: From the start of study treatment to 6 months, with disease assessments at the end of Cycles 1, 2, and 4, and every 3 cycles thereafter (each cycle is 28 days).

PFS6 is the percent probability estimate at 6 months based on the Kaplan-Meier method. PFS is measured from the start of study treatment to the first documented disease progression or death from any cause, whichever occurs first. Participants alive without disease progression are censored at the date of last follow-up. Disease progression is defined according to the ELN 2017 criteria as a >50% increase in bone marrow blasts from baseline (with a minimum 15-percentage-point increase for patients with <30% blasts at baseline), persistent bone marrow blasts >70% for at least 3 months without the specified hematologic improvement, a >50% increase in peripheral blood blasts to >25 × 10⁹/L in the absence of differentiation syndrome, or the development of new extramedullary disease.

From the start of study treatment to 6 months, with disease assessments at the end of Cycles 1, 2, and 4, and every 3 cycles thereafter (each cycle is 28 days).
12-month Progression-Free Survival (PFS12)
Tijdsspanne: From the start of study treatment to 12 months, with disease assessments at the end of Cycles 1, 2, and 4, and every 3 cycles thereafter (each cycle is 28 days).

PFS12 is the percent probability estimate at 12 months based on the Kaplan-Meier method. PFS is measured from the start of study treatment to the first documented disease progression or death from any cause, whichever occurs first. Participants alive without disease progression are censored at the date of last follow-up. Disease progression is defined according to the ELN 2017 criteria as a >50% increase in bone marrow blasts from baseline (with a minimum 15-percentage-point increase for patients with <30% blasts at baseline), persistent bone marrow blasts >70% for at least 3 months without the specified hematologic improvement, a >50% increase in peripheral blood blasts to >25 × 10⁹/L in the absence of differentiation syndrome, or the development of new extramedullary disease.

From the start of study treatment to 12 months, with disease assessments at the end of Cycles 1, 2, and 4, and every 3 cycles thereafter (each cycle is 28 days).
6-month Overall Survival (OS6)
Tijdsspanne: At 6 months after the start of study treatment

OS6 is the percent probability estimate at 6 months based on the Kaplan-Meier method. OS is defined as the time from start of study treatment to death due to any cause or censored at date last known alive. All surviving participants will be censored at time of final follow up.

At 6 months after the start of study treatment
12-month Overall Survival (OS12)
Tijdsspanne: At 12 months after the start of study treatment

OS12 is the percent probability estimate at 12 months based on the Kaplan-Meier method. OS is defined as the time from start of study treatment to death due to any cause or censored at date last known alive. All surviving participants will be censored at time of final follow up.

At 12 months after the start of study treatment

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Jacqueline S Garcia, MD, Dana-Farber Cancer Institute

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

6 maart 2027

Primaire voltooiing (Geschat)

31 december 2029

Studie voltooiing (Geschat)

31 juli 2030

Studieregistratiedata

Eerst ingediend

14 november 2026

Eerst ingediend dat voldeed aan de QC-criteria

14 november 2026

Eerst geplaatst (Werkelijk)

19 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

19 november 2026

Laatste update ingediend die voldeed aan QC-criteria

14 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

The Harvard Cancer Consortium encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: Jacqueline Garcia. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

IPD-tijdsbestek voor delen

Data can be shared no earlier than 1 year following the date of publication

IPD-toegangscriteria voor delen

Contact the Belfer office for Dana -Farber Innovations (BODFI) at innovations@dfci.harvard.edu

IPD delen Ondersteunend informatietype

  • LEERPROTOCOOL
  • SAP

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Ja

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren